Hypofractionated radiotherapy (RT) combined with dihydroartemisinin (DHA): No synergistic effect observed in a preliminary animal study.

IF 3.6 Q4 Medicine
Precision Radiation Oncology Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI:10.1002/pro6.70002
Yuenan Wang, Xiaodong Yang, Haitao Xiao, Fada Guan, Sanjay Aneja
{"title":"Hypofractionated radiotherapy (RT) combined with dihydroartemisinin (DHA): No synergistic effect observed in a preliminary animal study.","authors":"Yuenan Wang, Xiaodong Yang, Haitao Xiao, Fada Guan, Sanjay Aneja","doi":"10.1002/pro6.70002","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Dihydroartemisinin (DHA) is an anti-malaria agent and recent evidence indicates a broad anti-cancer activity. Radiotherapy (RT) is the cornerstone of cancer treatment and often has synergistic effects when combined with chemotherapy or targeted therapy. We aim to investigate whether synergistic effect exists for RT combined with DHA in a preliminary animal study of CRC treatment.</p><p><strong>Methods: </strong>Twenty-four BALB/c nude mice were subcutaneously injected with 5.0 × 10<sup>6</sup> cells of the murine CRC cell line CT26. When tumor xenografts were formed (∼ 100 mm<sup>3</sup>), mice were randomly allocated into four groups (n = 6 per group) and the tumor-bearing mice were intra-abdominally injected at Day 7, 9, 11 with PBS (control), 6Gy irradiation (RT), DHA (50mg/Kg), and DHA with irradiation (DHA+RT). All RT was performed on a medical linear accelerator using collimated anterior posterior 6MV photon beam conformal to tumor xenografts. The tumor volume was measured using an electronic caliper and was calculated based on the length (L) and the width of the tumor using the formula V = (L x W<sup>2</sup>)/2. Tumor weight was also measured after mice sacrificed. Histological assay was conducted, including using gammaH2AX for DNA double strand breaks (DSB) analysis.</p><p><strong>Results: </strong>The tumor weight was 2.4±0.8g, 2.5±0.6g, 0.4±0.2g, and 0.4±0.1g for the control, DHA, RT, and DHA+RT groups, respectively. Significant difference was observed between the control and RT groups, and between the control and DHA+RT groups (p<0.05). However, there was almost no difference between the RT alone and DHA+RT groups. The longitudinal change in tumor volume showed tumor progression inhibition in the RT and DHA+RT groups, but not so obvious in the DHA group, which was consistent with histological assay.</p><p><strong>Conclusion: </strong>Similar treatment efficacy is observed in the RT alone and concurrent DHA+RT group. No significant difference in tumor volume or weight or tumor progression inhibition is observed between the RT alone and concurrent DHA+RT groups, demonstrating that DHA might not provide synergistic effect with RT for the proposed hypofractionated radiation dose regimen.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"9 1","pages":"54-60"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12559898/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pro6.70002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Dihydroartemisinin (DHA) is an anti-malaria agent and recent evidence indicates a broad anti-cancer activity. Radiotherapy (RT) is the cornerstone of cancer treatment and often has synergistic effects when combined with chemotherapy or targeted therapy. We aim to investigate whether synergistic effect exists for RT combined with DHA in a preliminary animal study of CRC treatment.

Methods: Twenty-four BALB/c nude mice were subcutaneously injected with 5.0 × 106 cells of the murine CRC cell line CT26. When tumor xenografts were formed (∼ 100 mm3), mice were randomly allocated into four groups (n = 6 per group) and the tumor-bearing mice were intra-abdominally injected at Day 7, 9, 11 with PBS (control), 6Gy irradiation (RT), DHA (50mg/Kg), and DHA with irradiation (DHA+RT). All RT was performed on a medical linear accelerator using collimated anterior posterior 6MV photon beam conformal to tumor xenografts. The tumor volume was measured using an electronic caliper and was calculated based on the length (L) and the width of the tumor using the formula V = (L x W2)/2. Tumor weight was also measured after mice sacrificed. Histological assay was conducted, including using gammaH2AX for DNA double strand breaks (DSB) analysis.

Results: The tumor weight was 2.4±0.8g, 2.5±0.6g, 0.4±0.2g, and 0.4±0.1g for the control, DHA, RT, and DHA+RT groups, respectively. Significant difference was observed between the control and RT groups, and between the control and DHA+RT groups (p<0.05). However, there was almost no difference between the RT alone and DHA+RT groups. The longitudinal change in tumor volume showed tumor progression inhibition in the RT and DHA+RT groups, but not so obvious in the DHA group, which was consistent with histological assay.

Conclusion: Similar treatment efficacy is observed in the RT alone and concurrent DHA+RT group. No significant difference in tumor volume or weight or tumor progression inhibition is observed between the RT alone and concurrent DHA+RT groups, demonstrating that DHA might not provide synergistic effect with RT for the proposed hypofractionated radiation dose regimen.

Abstract Image

Abstract Image

Abstract Image

低分割放疗(RT)联合双氢青蒿素(DHA):在初步动物研究中未观察到增效作用。
目的:结直肠癌(CRC)是全球癌症相关死亡的主要原因之一。双氢青蒿素(DHA)是一种抗疟疾药物,最近的证据表明其具有广泛的抗癌活性。放射治疗(RT)是癌症治疗的基石,与化疗或靶向治疗联合使用时往往具有协同效应。我们的目的是在CRC治疗的初步动物研究中研究RT与DHA是否存在协同效应。方法:24只BALB/c裸鼠皮下注射小鼠CRC细胞系CT26细胞5.0 × 106个。当肿瘤形成(~ 100 mm3)时,将小鼠随机分为四组(每组n = 6),于第7、9、11天腹腔注射PBS(对照)、6Gy照射(RT)、DHA (50mg/Kg)和DHA联合照射(DHA+RT)。所有放射治疗均在医用直线加速器上进行,采用与异种肿瘤适形的前后侧准直6MV光子束。使用电子卡尺测量肿瘤体积,根据肿瘤的长度(L)和宽度(V = (L x W2)/2)计算肿瘤体积。并在小鼠牺牲后测量肿瘤重量。进行组织学分析,包括使用gammaH2AX进行DNA双链断裂(DSB)分析。结果:对照组、DHA组、RT组、DHA+RT组肿瘤重量分别为2.4±0.8g、2.5±0.6g、0.4±0.2g、0.4±0.1g。对照组与放化疗组、对照组与DHA+放化疗组的疗效差异有统计学意义(p)。结论:单独放化疗组与DHA+放化疗组疗效相近。单独放疗组和同时DHA+放疗组在肿瘤体积、重量和肿瘤进展抑制方面均未观察到显著差异,这表明DHA可能不会在拟议的低分割放射剂量方案中与RT产生协同作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Precision Radiation Oncology
Precision Radiation Oncology Medicine-Oncology
CiteScore
1.20
自引率
0.00%
发文量
32
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书